Ero Copper Corp (ERO)vsSanofi ADR (SNY)
ERO
Ero Copper Corp
$25.41
+2.87%
BASIC MATERIALS · Cap: $2.65B
SNY
Sanofi ADR
$46.03
+1.97%
HEALTHCARE · Cap: $109.03B
Smart Verdict
WallStSmart Research — data-driven comparison
Sanofi ADR generates 5845% more annual revenue ($46.72B vs $785.84M). ERO leads profitability with a 33.6% profit margin vs 16.7%. ERO trades at a lower P/E of 10.0x. ERO earns a higher WallStSmart Score of 68/100 (B-).
ERO
Strong Buy68
out of 100
Grade: B-
SNY
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-83.1%
Fair Value
$17.20
Current Price
$25.41
$8.21 premium
Margin of Safety
-89.7%
Fair Value
$24.79
Current Price
$46.03
$21.24 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Every $100 of equity generates 35 in profit
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 43.6%
Revenue surging 161.3% year-over-year
Reasonable price relative to book value
Reasonable price relative to book value
Large-cap with strong market position
Generating 1.6B in free cash flow
Areas to Watch
Earnings declined 11.0%
2.4% earnings growth
ROE of 6.7% — below average capital efficiency
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : ERO
The strongest argument for ERO centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 33.6% and operating margin at 43.6%. Revenue growth of 161.3% demonstrates continued momentum.
Bull Case : SNY
The strongest argument for SNY centers on Price/Book, Market Cap, Free Cash Flow. Profitability is solid with margins at 16.7% and operating margin at 14.3%.
Bear Case : ERO
The primary concerns for ERO are EPS Growth.
Bear Case : SNY
The primary concerns for SNY are EPS Growth, Return on Equity, PEG Ratio.
Key Dynamics to Monitor
ERO profiles as a growth stock while SNY is a mature play — different risk/reward profiles.
ERO carries more volatility with a beta of 1.51 — expect wider price swings.
ERO is growing revenue faster at 161.3% — sustainability is the question.
SNY generates stronger free cash flow (1.6B), providing more financial flexibility.
Bottom Line
ERO scores higher overall (68/100 vs 49/100), backed by strong 33.6% margins and 161.3% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Ero Copper Corp
BASIC MATERIALS · COPPER · USA
Ero Copper Corp. The company is headquartered in Vancouver, Canada.
Sanofi ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Sanofi, a healthcare company, is engaged in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company is headquartered in Paris, France.
Compare with Other COPPER Stocks
Want to dig deeper into these stocks?